Ligand Pharmaceuticals Incorporated (LGND)

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis. Further, the company develops ACLX-002, Ciforadenant, UGN-301, Viright, MB07133, BOT/BAL, and Lasofoxifene for oncology; Ensifentrine for respiratory disease; QTORIN for rare disease; Sparsentan for kidney disease; VK2809 for hepatology; ANEB-001 for acute cannabinoid intoxication; Reproxalap for opthamology; VK0214 for Rare Disease; and VK5211 for musculoskeletal disorder. The company was incorporated in 1987 and is based in Jupiter, Florida.

Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.

Super investor ownership

7 of the funds we track reported a position in their latest SEC 13F filing. Largest first:

• Impax Asset Management, Impax Asset Management Group plc$41.09M · 0.3% of book
• Ken Fisher, Fisher Asset Management, LLC$38.39M · 0.0% of book
• D. E. Shaw, D. E. Shaw & Co., Inc.$17.86M · 0.0% of book
• Two Sigma, TWO SIGMA INVESTMENTS, LP$5.95M · 0.0% of book
• Cliff Asness, AQR CAPITAL MANAGEMENT LLC$3.30M · 0.0% of book

A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.

Politician trades in LGND

Trades in LGND disclosed by members of Congress and executive-branch officials, latest first:

• Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 29 May 2026 · disclosed 8 Jun 2026
• Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 3 Mar 2026 · disclosed 7 Apr 2026
• Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 15 Jan 2026 · disclosed 13 Feb 2026
• Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 5 Jan 2026 · disclosed 13 Feb 2026

A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.

Common questions